Precursor lesions of endocrine system neoplasms

Pathology

Volumn 45, Issue 3, 2013, Pages 316-330

  Mete, Ozgur ^a,b   Asa, Sylvia L ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adenoma carcinoma sequence; Adrenal medullary hyperplasia; C cell hyperplasia; Dipnech; Endocrine cell hyperplasia; Follicular epithelial dysplasia; Microadenoma; Multiple endocrine neoplasia; Neuroendocrine tumour; Pituitary adenoma; Precursor lesions; Tumourlets

Indexed keywords

EID: 84879641891     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835f45c5     Document Type: Article

References (129)

1. Asa SL. The Atlas of Tumor Pathology. Tumors of the Pituitary Gland. Fascicle 15, 4th Series. Washington DC, Armed Forces Institute of Pathology, 2011.
2. Mete O, Asa SL. Clinicopathological correlations in pituitary adenomas. Brain Pathol 2012; 22: 443-53.
3. Mete O, Asa SL. Pituitary adenomas. In: Nose V, Erickson L, Tischler A, Asa SL, Lopes B. Diagnostic Pathology: Endocrine. Salt Lake City: Amirsys, 2012; 20-25.
4. Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Annu Rev Pathol 2009; 4: 97-126.
5. DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004.
6. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 2010; 24: 355-70.
7. Tichomirowa MA, Lee M, Barlier A, et al. Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocr Relat Cancer 2012; 19: 233-41.
8. Vortmeyer AO, Gläsker S, Mehta GU, et al. SomaticGNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome. J Clin Endocrinol Metab 2012; 97: 2404-13.
9. Trouillas J, Labat-Moleur F, Sturm N, et al. Groupe d'études des Tumeurs Endocrines. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008; 32: 534-43.
10. Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). J Clin Endocrinol Metab 2000; 85: 3860-5.
11. Kovacs K, Horvath E, Thorner MO, Rogol AD. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Arch A Pathol Anat Histopathol 1984; 403: 77-86.
12. Scheithauer BW, Kovacs K, Randall RV. The pituitary gland in untreated Addison's disease. A histologic and immunocytologic study of 18 adenohypophyses. Arch Pathol Lab Med 1983; 107: 484-7.
13. Scheithauer BW, Kovacs K, Randall RV, Ryan N. Pituitary gland in hypothyroidism. Histologic and immunocytologic study. Arch Pathol Lab Med 1985; 109: 499-504.
14. Kovacs K, Horvath E, Rewcastle NB, Ezrin C. Gonadotroph cell adenoma of the pituitary in a woman with long-standing hypogonadism. Arch Gynecol 1980; 229: 57-65.
15. Asa SL, Scheithauer BW, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 1984; 58: 796-803.
16. Ezzat S, Asa SL, Stefaneanu L, et al. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormonereleasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab 1994; 78: 555-60.
17. Puchner MJ, Lüdecke DK, Valdueza JM, et al. Cushing's disease in a child caused by a corticotropin-releasing hormone-secreting intrasellar gangliocytoma associated with an adrenocorticotropic hormonesecreting pituitary adenoma. Neurosurgery 1993; 33: 920-4; discussion 924-5.
18. Asa SL. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 2008; 132: 1231-40.
19. Al-Brahim NY, Asa SL. My approach to pathology of the pituitary gland. J Clin Pathol 2006; 59: 1245-53.
20. Mete O, Asa SL. Composite medullary and papillary thyroid carcinoma in a patient with MEN 2B: case report and review of C-cell lesions of the thyroid. Pathol Case Rev 2009; 14: 208-13.
21. LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997; 82: 39-41.
22. Lloyd RV. Endocrine Pathology: Differential Diagnosis and Molecular Advances. New Jersey: Humana Press, 2004.
23. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer 1995; 76: 2312-8.
24. Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg 2005; 71: 874-8.
25. Mete O, Asa SL. Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol 2010; 21: 16-24.
26. Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol 2012; 19: 363-73.
27. Chui MH, Cassol C, Asa SL, Mete O. Follicular epithelial dysplasia of the thyroid: morphologic and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Arch 2013; 462: in press.
28. Boerner SL, Asa SL. Biopsy Interpretation of the Thyroid. Philadelphia: Lippincott Williams & Wilkins, 2010.
29. Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL. Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 1995; 4: 113-21.
30. Kopp P, Kimura ET, Aeschimann S, et al. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 1994; 79: 134-9.
31. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 2002; 160: 2157-67.
32. Aherne ST, Smyth PC, Flavin RJ, et al. Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis and miRNA profiling. Mol Cancer 2008; 7: 89.
33. Son EJ, Nosé V. Familial follicular cell-derived thyroid carcinoma. Front Endocrinol (Lausanne) 2012; 3: 61.
34. Dotto J, Nosé V. Familial thyroid carcinoma: a diagnostic algorithm. Adv Anat Pathol 2008; 15: 332-49.
35. Zambrano E, Holm I, Glickman J, et al. Abnormal distribution and hyperplasia of thyroid C-cells in PTEN-associated tumor syndromes. Endocr Pathol 2004; 15: 55-64.
36. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Virchows Arch 1997; 431: 1-9.
37. Tubbs RR, Stoler MH. Cell and Tissue Based Molecular Pathology. Philadelphia: Churchill Livingstone Elsevier, 2009; 296-304.
38. Lai AZ, Gujral TS, Mulligan LM. RET signaling in endocrine tumors: delving deeper into molecular mechanisms. Endocr Pathol 2007; 18: 57-67.
39. de Groot JW, Links TP, Plukker JT, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006; 27: 535-60.
40. Allen SM, Bodenner D, Suen JY, Richter GT. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma. Laryngoscope 2009; 119: 1303-11.
41. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008; 21 (Suppl 2): 37-43.
42. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996; 56: 2167-70.
43. Wohllk N, Schweizer H, Erlic Z, et al. Multiple endocrine neoplasia type 2. Best Pract Res Clin Endocrinol Metab 2010; 24: 371-87.
44. Oertli D, Udelsman R. Surgery of the Thyroid and Parathyroid Glands. New York: Springer, 2007; 13-20.
45. Adams MS, Bronner-Fraser M. Review: the role of neural crest cells in the endocrine system. Endocr Pathol 2009; 20: 92-100.
46. Mete O, Rotstein L, Asa SL. Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol 2010; 17: 386-91.
47. Schäffer R, Müller HA, Pfeifer U, et al. Cytological findings in medullary carcinoma of the thyroid. Pathol Res Pract 1984; 178: 461-6.
48. Rosai J, Kuhn E, Carcangiu ML. Pitfalls in thyroid tumour pathology. Histopathology 2006; 49: 107-20.
49. Pichardo-Lowden AR, Manni A, Saunders BD, Baker MJ. Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. Endocr Pract 2011; 17: 602-9.
50. Wang PF, Tan MH, Zhang C, Morreau H, Teh BT. HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome. Horm Metab Res 2005; 37: 380-3.
51. Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 2010; 24: 491-502.
52. Erickson LA, Lloyd RV. Familial disorders of the parathyroid gland. Diagn Histopathol 2009; 15: 79-86.
53. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005; 42: 35-70.
54. Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cellsurface receptors. N Engl J Med 1995; 333: 234-40.
55. Agha A, Carpenter R, Bhattacharya S, Edmonson SJ, Carlsen E, Monson JP. Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 2007; 30: 145-9.
56. del Pozo C, García-Pascual L, Balsells M, et al. Parathyroid carcinoma in multiple endocrine neoplasia type 1. Case report and review of the literature. Hormones (Athens) 2011; 10: 326-31.
57. Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002; 77: 866-9.
58. Dreijerink KM, Varier RA, van Nuland R, et al. Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas. Mol Cell Endocrinol 2009; 313: 1-8.
59. Erovic BM, Harris L, Jamali M, et al. Biomarkers of parathyroid carcinoma. Endocr Pathol 2012; 23: 221-31.
60. Erovic BM, Goldstein DP, Kim D, et al. Parathyroid cancer: Outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck 2013; 35: 35-9.
61. Djema AI, Mahmoud MD, Collin P, Heymann MF. Tertiary hyperparathyroidism: parathyroid cancer with liver metastases in a hemodialyzed patient. Nephrologie 1998; 19: 121-3.
62. Obregón LM, Taylor MF, Mir G, et al. Parathyroidectomy for parathyroid carcinoma in renal transplantation. Transplant Proc 2005; 37: 973-6.
63. Bossola M, Tazza L, Ferrante A, et al. Parathyroid carcinoma in a chronic hemodialysis patient: case report and review of the literature. Tumori 2005; 91: 558-62.
64. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
65. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: Evidence for separate biological entities. Biochim Biophys Acta 2012; 1826: 255-71.
66. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol 2010; 21 (Suppl 7): vii 65-71.
67. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. The molecular basis of lung morphogenesis. Mech Dev 2000; 92: 55-81.
68. Sidhu GS. The endodermal origin of digestive and respiratory tract APUDcells. Histopathologic evidence and a review of the literature. Am J Pathol 1979; 96: 5-20.
69. Linnoila RI. Functional facets of the pulmonary neuroendocrine system. Lab Invest 2006; 86: 425-44.
70. Boers JE, den Brok JL, Koudstaal J, Arends JW, Thunnissen FB. Number and proliferation of neuroendocrine cells in normal human airway epithelium. Am J Respir Crit Care Med 1996; 154: 758-63.
71. Ball DW. Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. Cancer Lett 2004; 204: 159-69.
72. Li Y, Linnoila I. Multi-directional differentiation of Achaete-Scute homologue- 1-defined progenitors in lung development and injury repair. Am J Respir Cell Mol Biol 2012; 47: 768-75.
73. Gosney JR. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors. Chest 2004; 125 (5 Suppl): 108S.
74. Miller YE. Does unilateral DIPNECH provide clues to pathogenesis? J Thorac Oncol 2010; 5: 761-2.
75. Gosney JR, Williams IJ, Dodson AR, Foster CS. Morphology and antigen expression profile of pulmonary neuroendocrine cells in reactive proliferations and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH). Histopathology 2011; 59: 751-62.
76. De Giorgi U, Fanini F, Amadori D, et al. Tumorlets in familial history of bronchopulmonary carcinoid. J Thorac Oncol 2011; 6: 1613-4.
77. Hausman DH, Weimann RB. Pulmonary tumorlet with hilar lymph node metastasis. Report of a case. Cancer 1967; 20: 1515-9.
78. Dogan R, Kara M, Gundogdu AG, Firat P. An underrated potential risk of bronchiectasis: lymph node metastasis of a pulmonary tumorlet. Acta Chir Belg 2009; 109: 109-11.
79. Finkelstein SD, Hasegawa T, Colby T, Yousem SA. 11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection- based genotyping approach useful in clinical practice. Am J Pathol 1999; 155: 633-40.
80. Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumors of the Digestive System. IARC: Lyon, 2010.
81. Rindi G. Clinicopathologic aspects of gastric neuroendocrine tumors. Am J Surg Pathol 1995; 19 (Suppl 1): S20-9.
82. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-72.
83. Delle Fave G, Marignani M, Corleto VD, et al. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients. Dig Liver Dis 2002; 34: 270-8.
84. Klöppel G, Anlauf M, Perren A. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors. Endocr Pathol 2007; 18: 150-5.
85. Anlauf M, Garbrecht N, Bauersfeld J, et al. Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 2007; 451 (Suppl 1): S29-S38.
86. Rindi G, Paolotti D, Fiocca R, Wiedenmann B, Henry JP, Solcia E. Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin- like cell tumors. Virchows Arch 2000; 436: 217-23.
87. Bordi C, D'Adda T, Azzoni C, Canavese G, Brandi ML. Gastrointestinal endocrine tumors: recent developments. Endocr Pathol 1998; 9: 99-115.
88. Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 2001; 13: 1449-56.
89. Solcia E, Rindi G, Larosa S, Capella C. Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microsc Res Tech 2000; 15: 339-48.
90. Bordi C, D'Adda T, Azzoni C, Ferraro G. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998; 71: 273-84.
91. Tang LH, Modlin IM, Lawton GP, Kidd M, Chinery R. The role of transforming growth factor alpha in the enterochromaffin-like cell tumor autonomy in an African rodent mastomys. Gastroenterology 1996; 111: 1212-23.
92. Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93: 1582-91.
93. Asa SL. Pancreatic endocrine tumors. Mod Pathol 2011; 24 (Suppl 2): S66-S77.
94. Gledhill A, Hall PA, Cruse JP, Pollock DJ. Enteroendocrine cell hyperplasia, carcinoid tumours and adenocarcinoma in long-standing ulcerative colitis. Histopathology 1986; 10: 501-8.
95. McNeely B, Owen DA, Pezim M. Multiple microcarcinoids arising in chronic ulcerative colitis. Am J Clin Pathol 1992; 98: 112-6.
96. West NE, Wise PE, Herline AJ, Muldoon RL, Chopp WV, Schwartz DA. Carcinoid tumors are 15 times more common in patients with Crohn's disease. Inflamm Bowel Dis 2007; 13: 1129-34.
97. Chetty R. Pancreatic endocrine neoplasia: familial syndromes. Diagn Histopathol 2009; 15: 95-8.
98. Chetty R, Kennedy M, Ezzat S, Asa SL. Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. Endocr Pathol 2004; 15: 141-8.
99. Chetty R, Ezzat S, Asa SL. Microadenomatosis of the pancreas in von Hippel-Lindau disease. Am J Surg Pathol 2006; 30: 1630.
100. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006; 30: 560-74.
101. Périgny M, Hammel P, Corcos O, et al. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease:characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol 2009; 33: 739-48.
102. Akatsu T, Aiura K, Ito Y, Ueda M, Kameyama K, Kitajima M. A novel Von Hippel-Lindau case with germline mutation at codon 167 (CGG to TGG) having endocrine microadenomatosis of the pancreas. Dig Dis Sci 2007; 52: 3145-8.
103. Atiq M, Gong Y, Raju GS, Lee JH. Pancreatic endocrine microadenomatosis in a patient with oculofaciocardiodental (OFCD) syndrome. Pancreas 2012; 41: 327-9.
104. Lack EE. AFIP Atlas of Tumor Pathology. Tumors of the Adrenal Glands and Extraadrenal Paraganglia. Washington, DC: ARP Press, 2007.
105. van Nederveen FH, de Krijger RR. Precursor lesions of the adrenal gland. Pathobiology 2007; 74: 285-90.
106. Hunt JL. Syndromes associated with abnormalities in the adrenal cortex. Diagn Histopathol 2009; 15: 69-78.
107. Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010; 24: 389-99.
108. Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 2012; 351: 66-70.
109. Ribeiro RC, Pinto EM, Zambetti GP. Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract Res Clin Endocrinol Metab 2010; 24: 477-90.
110. Morin E, Mete O, Wasserman JD, Joshua AM, Asa SL, Ezzat S. Carney complex with adrenal cortical carcinoma. J Clin Endocrinol Metab 2012; 97: E202-6.
111. Anselmo J, Medeiros S, Carneiro V, et al. A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer. J Clin Endocrinol Metab 2012; 97: 351-9.
112. Choi M, Scholl UI, Yue P, et al. K channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-72.
113. Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97: 1311-9.
114. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomaldominant hypertension. J Clin Endocrinol Metab 2012; 97:E1532-9.
115. Libé R, Fratticci A, Coste J, et al. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14: 4016-24.
116. de Krijger RR, Papathomas TG. Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. Virchows Arch 2012; 460: 9-18.
117. Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005; 65: 7622-7.
118. Heaton JH, Wood MA, Kim AC, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and b-catenin. Am J Pathol 2012; 181: 1017-33.
119. Gaujoux S, Pinson S, Gimenez-Roqueplo AP, et al. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res 2010; 16: 5133-41.
120. Seki M, Tanaka K, Kikuchi-Yanoshita R, et al. Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 1992; 89: 298-300.
121. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 2008; 132: 1272-84.
122. McNicol AM. Adrenal medulla and paraganglia. In: Lloyd RV, editor. Endocrine Pathology: Differential Diagnosis and Molecular Advances. New York: Springer, 2010; 281-95.
123. Cascon A, Tennant DA. From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma. Endocr Pathol 2012; 23: 15-20.
124. Burnichon N, Cascón A, Schiavi F, et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012; 18: 2828-37.
125. Qin Y, Yao L, King EE, et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010; 42: 229-33.
126. Buffet A, Venisse A, Nau V, et al. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: 359-66.
127. Yeh IT, Lenci RE, Qin Y, et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 2008; 124: 279-85.
128. Asa SL, Fischer SE. Adrenal gland. In: Gattuso P, Reddy VB, David O, Spitz DJ, Haber MH, editors. Differential Diagnosis in Surgical Pathology. Philadelphia: Saunders Elsevier, 2010; 461-85.
129. Grogan RH, Pacak K, Pasche L, Huynh TT, Greco RS. Bilateral adrenal medullary hyperplasia associated with an SDHB mutation. J Clin Oncol 2011:29; e200-2.